Aromatase Inhibitors and Plasma Lipid Changes in Postmenopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis

Background: Women are typically diagnosed with estrogen receptor-positive breast cancer around the postmenopausal period when declining estrogen levels initiate changes in lipid profiles. Aromatase inhibitors (AI) are used to prevent the progression of cancer; however, a further reduction in estroge...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical medicine Vol. 13; no. 6; p. 1818
Main Authors Bérczi, Bálint, Farkas, Nelli, Hegyi, Péter, Tóth, Barbara, Csupor, Dezső, Németh, Balázs, Lukács, Anita, Czumbel, László Márk, Kerémi, Beáta, Kiss, István, Szabó, Andrea, Varga, Gábor, Gerber, Gábor, Gyöngyi, Zoltán
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 21.03.2024
MDPI
Subjects
Algorithms
Analysis
Blood cholesterol
Breast cancer
Cancer
Cardiac patients
Care and treatment
Cholesterol
Development and progression
Diagnosis
Drug therapy
Dyslipidemias
Estrogen
Estrogens
High density lipoprotein
Keywords
Libraries
Lipids
Medical research
Medicine, Experimental
Meta-analysis
Metabolic disorders
Postmenopausal women
Prevention
Risk factors
Science
Systematic Review
Tamoxifen
Womens health
Hungary
United States > US
letrozole
meta-analysis
breast cancer
exemestane
lipids
anastrozole
Online AccessGet full text
ISSN2077-0383
2077-0383
DOI10.3390/jcm13061818

Cover

Abstract Background: Women are typically diagnosed with estrogen receptor-positive breast cancer around the postmenopausal period when declining estrogen levels initiate changes in lipid profiles. Aromatase inhibitors (AI) are used to prevent the progression of cancer; however, a further reduction in estrogen levels may have detrimental effects on lipid levels, which was our working hypothesis. Methods: Our meta-analysis was conducted on the lipid profiles of postmenopausal breast cancer patients at baseline and at different treatment time points. Results: We identified 15 studies, including 1708 patients. Studies using anastrozole (ANA), exemestane (EXE), letrozole (LET), and tamoxifen (TMX) were involved. Subgroup analyses revealed that 3- and 12-month administrations of LET and EXE lead to negative changes in lipid profiles that tend to alter the lipid profile undesirably, unlike ANA and TMX. Conclusions: Our results suggest that, despite statistically significant results, EXE and LET may not be sufficient to cause severe dyslipidemia in patients without cardiovascular comorbidities according to the AHA/ACC Guideline on the Management of Blood Cholesterol. However, the results may raise the question of monitoring the effects of AIs in patients, especially those with pre-existing cardiovascular risk factors such as dyslipidemia.
AbstractList Background: Women are typically diagnosed with estrogen receptor-positive breast cancer around the postmenopausal period when declining estrogen levels initiate changes in lipid profiles. Aromatase inhibitors (AI) are used to prevent the progression of cancer; however, a further reduction in estrogen levels may have detrimental effects on lipid levels, which was our working hypothesis. Methods: Our meta-analysis was conducted on the lipid profiles of postmenopausal breast cancer patients at baseline and at different treatment time points. Results: We identified 15 studies, including 1708 patients. Studies using anastrozole (ANA), exemestane (EXE), letrozole (LET), and tamoxifen (TMX) were involved. Subgroup analyses revealed that 3- and 12-month administrations of LET and EXE lead to negative changes in lipid profiles that tend to alter the lipid profile undesirably, unlike ANA and TMX. Conclusions: Our results suggest that, despite statistically significant results, EXE and LET may not be sufficient to cause severe dyslipidemia in patients without cardiovascular comorbidities according to the AHA/ACC Guideline on the Management of Blood Cholesterol. However, the results may raise the question of monitoring the effects of AIs in patients, especially those with pre-existing cardiovascular risk factors such as dyslipidemia.
Background: Women are typically diagnosed with estrogen receptor-positive breast cancer around the postmenopausal period when declining estrogen levels initiate changes in lipid profiles. Aromatase inhibitors (AI) are used to prevent the progression of cancer; however, a further reduction in estrogen levels may have detrimental effects on lipid levels, which was our working hypothesis. Methods: Our meta-analysis was conducted on the lipid profiles of postmenopausal breast cancer patients at baseline and at different treatment time points. Results: We identified 15 studies, including 1708 patients. Studies using anastrozole (ANA), exemestane (EXE), letrozole (LET), and tamoxifen (TMX) were involved. Subgroup analyses revealed that 3- and 12-month administrations of LET and EXE lead to negative changes in lipid profiles that tend to alter the lipid profile undesirably, unlike ANA and TMX. Conclusions: Our results suggest that, despite statistically significant results, EXE and LET may not be sufficient to cause severe dyslipidemia in patients without cardiovascular comorbidities according to the AHA/ACC Guideline on the Management of Blood Cholesterol. However, the results may raise the question of monitoring the effects of AIs in patients, especially those with pre-existing cardiovascular risk factors such as dyslipidemia.
Women are typically diagnosed with estrogen receptor-positive breast cancer around the postmenopausal period when declining estrogen levels initiate changes in lipid profiles. Aromatase inhibitors (AI) are used to prevent the progression of cancer; however, a further reduction in estrogen levels may have detrimental effects on lipid levels, which was our working hypothesis. Our meta-analysis was conducted on the lipid profiles of postmenopausal breast cancer patients at baseline and at different treatment time points. We identified 15 studies, including 1708 patients. Studies using anastrozole (ANA), exemestane (EXE), letrozole (LET), and tamoxifen (TMX) were involved. Subgroup analyses revealed that 3- and 12-month administrations of LET and EXE lead to negative changes in lipid profiles that tend to alter the lipid profile undesirably, unlike ANA and TMX. Our results suggest that, despite statistically significant results, EXE and LET may not be sufficient to cause severe dyslipidemia in patients without cardiovascular comorbidities according to the AHA/ACC Guideline on the Management of Blood Cholesterol. However, the results may raise the question of monitoring the effects of AIs in patients, especially those with pre-existing cardiovascular risk factors such as dyslipidemia.
Background: Women are typically diagnosed with estrogen receptor-positive breast cancer around the postmenopausal period when declining estrogen levels initiate changes in lipid profiles. Aromatase inhibitors (AI) are used to prevent the progression of cancer; however, a further reduction in estrogen levels may have detrimental effects on lipid levels, which was our working hypothesis. Methods: Our meta-analysis was conducted on the lipid profiles of postmenopausal breast cancer patients at baseline and at different treatment time points. Results: We identified 15 studies, including 1708 patients. Studies using anastrozole (ANA), exemestane (EXE), letrozole (LET), and tamoxifen (TMX) were involved. Subgroup analyses revealed that 3- and 12-month administrations of LET and EXE lead to negative changes in lipid profiles that tend to alter the lipid profile undesirably, unlike ANA and TMX. Conclusions: Our results suggest that, despite statistically significant results, EXE and LET may not be sufficient to cause severe dyslipidemia in patients without cardiovascular comorbidities according to the AHA/ACC Guideline on the Management of Blood Cholesterol. However, the results may raise the question of monitoring the effects of AIs in patients, especially those with pre-existing cardiovascular risk factors such as dyslipidemia.Background: Women are typically diagnosed with estrogen receptor-positive breast cancer around the postmenopausal period when declining estrogen levels initiate changes in lipid profiles. Aromatase inhibitors (AI) are used to prevent the progression of cancer; however, a further reduction in estrogen levels may have detrimental effects on lipid levels, which was our working hypothesis. Methods: Our meta-analysis was conducted on the lipid profiles of postmenopausal breast cancer patients at baseline and at different treatment time points. Results: We identified 15 studies, including 1708 patients. Studies using anastrozole (ANA), exemestane (EXE), letrozole (LET), and tamoxifen (TMX) were involved. Subgroup analyses revealed that 3- and 12-month administrations of LET and EXE lead to negative changes in lipid profiles that tend to alter the lipid profile undesirably, unlike ANA and TMX. Conclusions: Our results suggest that, despite statistically significant results, EXE and LET may not be sufficient to cause severe dyslipidemia in patients without cardiovascular comorbidities according to the AHA/ACC Guideline on the Management of Blood Cholesterol. However, the results may raise the question of monitoring the effects of AIs in patients, especially those with pre-existing cardiovascular risk factors such as dyslipidemia.
Audience Academic
Author Bérczi, Bálint
Németh, Balázs
Kiss, István
Tóth, Barbara
Lukács, Anita
Hegyi, Péter
Kerémi, Beáta
Czumbel, László Márk
Farkas, Nelli
Szabó, Andrea
Varga, Gábor
Csupor, Dezső
Gerber, Gábor
Gyöngyi, Zoltán
AuthorAffiliation 2 Institute for Translational Medicine, Medical School, University of Pécs, Szigeti út 12, 7624 Pécs, Hungary; nelli.farkas@aok.pte.hu (N.F.); hegyi.peter@pte.hu (P.H.); csupor.dezso@pharmacognosy.hu (D.C.)
4 First Department of Medicine, University of Szeged, Korányi Fasor 8-10, 6720 Szeged, Hungary
3 Institute of Bioanalysis, Medical School, University of Pécs, Szigeti út 12, 7624 Pécs, Hungary
1 Department of Public Health Medicine, Medical School, University of Pécs, Szigeti út 12, 7624 Pécs, Hungary; berczi.balint84@gmail.com (B.B.); balazs.nemeth@aok.pte.hu (B.N.); istvan.kiss@aok.pte.hu (I.K.)
8 Department of Oral Biology, Faculty of Dentistry, Semmelweis University, Nagyvárad tér 4, 1089 Budapest, Hungary; czumbel.laszlo@semmelweis.hu (L.M.C.); keremi.beata@dent.semmelweis-univ.hu (B.K.); varga.gabor@dent.semmelweis-univ.hu (G.V.)
7 Department of Public Health, Faculty of Medicine, University of Szeged, Dóm tér 10, 6720 Szeged, Hungary; lukacs.anita@med.u-szeged.hu (A.L.); szabo.and
AuthorAffiliation_xml – name: 5 Department of Pharmacognosy, University of Szeged, Eötvös u. 6, 6720 Szeged, Hungary; toth.barbara@pharmacognosy.hu
– name: 6 Interdisciplinary Centre of Natural Products, University of Szeged, Dugonics tér 13, 6720 Szeged, Hungary
– name: 3 Institute of Bioanalysis, Medical School, University of Pécs, Szigeti út 12, 7624 Pécs, Hungary
– name: 8 Department of Oral Biology, Faculty of Dentistry, Semmelweis University, Nagyvárad tér 4, 1089 Budapest, Hungary; czumbel.laszlo@semmelweis.hu (L.M.C.); keremi.beata@dent.semmelweis-univ.hu (B.K.); varga.gabor@dent.semmelweis-univ.hu (G.V.)
– name: 9 Department of Anatomy, Histology and Embryology, Faculty of Medicine, Semmelweis University, Tűzoltó u. 58, 1094 Budapest, Hungary; gerber.gabor@med.semmelweis-univ.hu
– name: 2 Institute for Translational Medicine, Medical School, University of Pécs, Szigeti út 12, 7624 Pécs, Hungary; nelli.farkas@aok.pte.hu (N.F.); hegyi.peter@pte.hu (P.H.); csupor.dezso@pharmacognosy.hu (D.C.)
– name: 4 First Department of Medicine, University of Szeged, Korányi Fasor 8-10, 6720 Szeged, Hungary
– name: 1 Department of Public Health Medicine, Medical School, University of Pécs, Szigeti út 12, 7624 Pécs, Hungary; berczi.balint84@gmail.com (B.B.); balazs.nemeth@aok.pte.hu (B.N.); istvan.kiss@aok.pte.hu (I.K.)
– name: 7 Department of Public Health, Faculty of Medicine, University of Szeged, Dóm tér 10, 6720 Szeged, Hungary; lukacs.anita@med.u-szeged.hu (A.L.); szabo.andrea@med.u-szeged.hu (A.S.)
Author_xml – sequence: 1
  givenname: Bálint
  orcidid: 0000-0001-9955-9901
  surname: Bérczi
  fullname: Bérczi, Bálint
– sequence: 2
  givenname: Nelli
  orcidid: 0000-0002-5349-6527
  surname: Farkas
  fullname: Farkas, Nelli
– sequence: 3
  givenname: Péter
  surname: Hegyi
  fullname: Hegyi, Péter
– sequence: 4
  givenname: Barbara
  surname: Tóth
  fullname: Tóth, Barbara
– sequence: 5
  givenname: Dezső
  orcidid: 0000-0002-4088-3333
  surname: Csupor
  fullname: Csupor, Dezső
– sequence: 6
  givenname: Balázs
  orcidid: 0000-0002-4914-9872
  surname: Németh
  fullname: Németh, Balázs
– sequence: 7
  givenname: Anita
  orcidid: 0000-0002-0746-8920
  surname: Lukács
  fullname: Lukács, Anita
– sequence: 8
  givenname: László Márk
  orcidid: 0000-0002-5915-0383
  surname: Czumbel
  fullname: Czumbel, László Márk
– sequence: 9
  givenname: Beáta
  surname: Kerémi
  fullname: Kerémi, Beáta
– sequence: 10
  givenname: István
  surname: Kiss
  fullname: Kiss, István
– sequence: 11
  givenname: Andrea
  orcidid: 0000-0003-4949-9431
  surname: Szabó
  fullname: Szabó, Andrea
– sequence: 12
  givenname: Gábor
  orcidid: 0000-0002-5506-8198
  surname: Varga
  fullname: Varga, Gábor
– sequence: 13
  givenname: Gábor
  orcidid: 0000-0003-0256-2608
  surname: Gerber
  fullname: Gerber, Gábor
– sequence: 14
  givenname: Zoltán
  orcidid: 0000-0001-9330-9119
  surname: Gyöngyi
  fullname: Gyöngyi, Zoltán
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38542042$$D View this record in MEDLINE/PubMed
BookMark eNptkstvEzEQh1eoiJbSE3dkiQsS2uLXxjaXaol4VAqi4iGOlteZTRzt2sF2WuXEv45DS0mr2ocZ29_8rHk8rQ588FBVzwk-ZUzhNys7EoYnRBL5qDqiWIgaM8kO9vzD6iSlFS5LSk6JeFIdMtlwijk9qn63MYwmmwTo3C9d53KICRk_RxeDSaNBM7d2czRdGr-AhJxHFyHlEXxYm00yA_oZygFdubxE7yKYlNHUeAvxLWrRt23KUNSdRV_h0sHVX-HPkE3dejNsk0vPqse9GRKc3Njj6seH99-nn-rZl4_n03ZWWy5ErieiB9k0VEqmLKfUWMV7xkFNLO4axQRvGgXY4r5vhOk62ndN11thOeO8WHZcnV3rrjfdCHMLPkcz6HV0o4lbHYzTd1-8W-pFuNQEK4GVbIrCqxuFGH5tIGU9umRhGIyHsEmaYcIxVlzQgr68h67CJpaMdxSmipTSk__Uwgygne9D-djuRHUrpKRcln4V6vQBquw5jM6WYehdub8T8GI_09sU__W8AK-vARtDShH6W4RgvRsqvTdUhSb3aOtyaWnYlckND8b8AYKUzfM
CitedBy_id crossref_primary_10_1002_slct_202401566
crossref_primary_10_1055_a_2543_4451
Cites_doi 10.1097/01.gme.0000218683.97338.ea
10.3390/jcm11113133
10.1080/02841860510007585
10.1136/bmjgh-2023-012312
10.1093/annonc/mdn545
10.1186/s13293-017-0152-8
10.1007/s10549-011-1608-x
10.1158/1940-6207.CAPR-15-0322
10.3389/fcvm.2022.895916
10.2174/092986713804999303
10.3389/fphar.2022.850815
10.1158/1078-0432.CCR-15-1213
10.3322/caac.21492
10.1016/j.beem.2022.101667
10.1016/j.metabol.2006.03.005
10.1002/9781119536604
10.1186/s12944-024-02002-6
10.1007/s11307-022-01795-1
10.1200/JCO.2005.07.097
10.1038/s41467-023-39613-z
10.1056/NEJMoa062462
10.1038/sj.bjc.6603258
10.1007/s10549-013-2573-3
10.1177/0091270011424153
10.1097/gme.0b013e3181dbdc30
10.1016/j.jacc.2018.11.002
10.1186/bcr2320
10.1007/978-3-319-70178-3_12
10.1093/annonc/mdv298
10.6004/jadpro.2023.14.6.2
10.4161/cbt.8.15.8959
10.1002/cpdd.420
10.1016/j.ejogrb.2024.01.021
10.1158/1940-6207.CAPR-15-0269
10.1002/lipd.12011
10.1634/theoncologist.2009-0222
10.3390/curroncol30020142
10.1093/jnci/djr242
10.7326/M14-2385
10.1016/j.cct.2015.09.002
10.1186/bcr2901
10.1161/ATVBAHA.118.310792
10.3109/13697137.2011.562994
10.1093/oxfordjournals.aje.a116686
10.1016/j.exger.2021.111680
10.1177/001316446002000104
10.1016/j.tem.2018.06.001
10.1093/aje/kwp043
10.1016/j.ejim.2007.05.016
10.1371/journal.pmed.1000097
10.1007/s40265-017-0767-4
ContentType Journal Article
Copyright COPYRIGHT 2024 MDPI AG
2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2024 by the authors. 2024
Copyright_xml – notice: COPYRIGHT 2024 MDPI AG
– notice: 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2024 by the authors. 2024
DBID AAYXX
CITATION
NPM
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.3390/jcm13061818
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection (Proquest)
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
CrossRef

PubMed
Publicly Available Content Database
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X7
  name: Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2077-0383
ExternalDocumentID PMC10970985
A788248884
38542042
10_3390_jcm13061818
Genre Journal Article
Review
GeographicLocations Hungary
United States--US
GeographicLocations_xml – name: Hungary
– name: United States--US
GrantInformation_xml – fundername: “GINOP-2.3.2-15-2016-00048—STAY ALIVE”; European Union (European Regional Development Fund)
– fundername: Human Resources Development Operational Programme; European Union (European Regional Development Fund)
  grantid: EFOP 3.6.2-16-2017-00006—LIVE LONGER
GroupedDBID 53G
5VS
7X7
8FI
8FJ
AADQD
AAFWJ
AAYXX
ABDBF
ABUWG
ACUHS
ADBBV
AFKRA
AFZYC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
BENPR
CCPQU
CITATION
DIK
FYUFA
HMCUK
HYE
IAO
IHR
ITC
KQ8
M48
MODMG
M~E
OK1
PGMZT
PHGZM
PHGZT
PIMPY
RPM
UKHRP
GROUPED_DOAJ
NPM
PMFND
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c477t-67fe85528839c422ac94f34e96c0b59374559e0c0ff57abb2fb5bfc7c4344fc73
IEDL.DBID M48
ISSN 2077-0383
IngestDate Thu Aug 21 18:35:37 EDT 2025
Thu Sep 04 16:00:03 EDT 2025
Sat Aug 23 13:02:30 EDT 2025
Tue Jun 17 22:15:28 EDT 2025
Tue Jun 10 21:11:03 EDT 2025
Thu Jan 02 22:27:50 EST 2025
Tue Jul 01 02:10:49 EDT 2025
Thu Apr 24 22:56:43 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords letrozole
meta-analysis
breast cancer
exemestane
lipids
anastrozole
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c477t-67fe85528839c422ac94f34e96c0b59374559e0c0ff57abb2fb5bfc7c4344fc73
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0002-0746-8920
0000-0003-0256-2608
0000-0001-9955-9901
0000-0002-4088-3333
0000-0003-4949-9431
0000-0002-5349-6527
0000-0002-5506-8198
0000-0002-5915-0383
0000-0002-4914-9872
0000-0001-9330-9119
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/jcm13061818
PMID 38542042
PQID 3002910421
PQPubID 5046890
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_10970985
proquest_miscellaneous_3014009472
proquest_journals_3002910421
gale_infotracmisc_A788248884
gale_infotracacademiconefile_A788248884
pubmed_primary_38542042
crossref_primary_10_3390_jcm13061818
crossref_citationtrail_10_3390_jcm13061818
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20240321
PublicationDateYYYYMMDD 2024-03-21
PublicationDate_xml – month: 3
  year: 2024
  text: 20240321
  day: 21
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Journal of clinical medicine
PublicationTitleAlternate J Clin Med
PublicationYear 2024
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Geisler (ref_30) 2005; 23
Siminzar (ref_4) 2023; 25
Zidan (ref_36) 2010; 15
ref_14
Korevaar (ref_18) 1993; 137
Zhu (ref_15) 2018; 29
Markopoulos (ref_33) 2009; 20
Ghaffari (ref_11) 2018; 38
Senkus (ref_50) 2015; 26
Mosca (ref_53) 2006; 355
Grundy (ref_45) 2019; 73
Alomar (ref_47) 2022; 159
ref_25
ref_23
Montagnani (ref_32) 2008; 19
Bray (ref_1) 2018; 68
Diffenderfer (ref_7) 2018; 53
Amir (ref_22) 2011; 103
ref_27
Camerini (ref_54) 2009; 8
Cohen (ref_28) 1960; 20
Sahebkar (ref_51) 2017; 77
Schuster (ref_6) 2023; 14
Sharma (ref_19) 2015; 19
Iwata (ref_39) 2013; 139
Nie (ref_13) 2022; 13
Patnaik (ref_20) 2011; 13
Yang (ref_55) 2024; 295
Li (ref_9) 2024; 23
Newman (ref_10) 2023; 37
Lumachi (ref_21) 2013; 20
Blackford (ref_40) 2016; 22
Yoshida (ref_49) 2011; 14
Francini (ref_31) 2006; 95
Xie (ref_12) 2022; 9
Markopoulos (ref_34) 2009; 11
Anan (ref_37) 2011; 128
Zhou (ref_17) 2010; 17
Hutton (ref_26) 2015; 162
Venzon (ref_42) 2016; 9
Buzdar (ref_46) 2001; 7
Heery (ref_56) 2023; 14
DerSimonian (ref_29) 2015; 45 Pt A
ref_3
ref_2
Sawada (ref_35) 2005; 44
Bell (ref_38) 2012; 52
Tian (ref_44) 2018; 7
Leone (ref_5) 2023; 8
Sahib (ref_43) 2017; 9
Atsma (ref_48) 2006; 13
Derby (ref_16) 2009; 169
Dayspring (ref_52) 2006; 55
Pruthi (ref_41) 2016; 9
Yoo (ref_24) 2023; 30
Palmisano (ref_8) 2017; 1043
References_xml – volume: 13
  start-page: 265
  year: 2006
  ident: ref_48
  article-title: Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: A meta-analysis
  publication-title: Menopause
  doi: 10.1097/01.gme.0000218683.97338.ea
– ident: ref_23
  doi: 10.3390/jcm11113133
– volume: 44
  start-page: 134
  year: 2005
  ident: ref_35
  article-title: Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer
  publication-title: Acta Oncol.
  doi: 10.1080/02841860510007585
– volume: 8
  start-page: e012312
  year: 2023
  ident: ref_5
  article-title: Secular trends in premature and early menopause in low-income and middle-income countries
  publication-title: BMJ Glob. Health
  doi: 10.1136/bmjgh-2023-012312
– volume: 20
  start-page: 49
  year: 2009
  ident: ref_33
  article-title: Lipid changes in breast cancer patients on exemestane treatment: Final results of the TEAM Greek substudy
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdn545
– ident: ref_14
  doi: 10.1186/s13293-017-0152-8
– volume: 128
  start-page: 775
  year: 2011
  ident: ref_37
  article-title: Effects of toremifene and anastrozole on serum lipids and bone metabolism in postmenopausal females with estrogen receptor-positive breast cancer: The results of a 2-year multicenter open randomized study
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-011-1608-x
– volume: 9
  start-page: 142
  year: 2016
  ident: ref_41
  article-title: Double-Blind, Randomized Trial of Alternative Letrozole Dosing Regimens in Postmenopausal Women with Increased Breast Cancer Risk
  publication-title: Cancer Prev. Res.
  doi: 10.1158/1940-6207.CAPR-15-0322
– volume: 9
  start-page: 895916
  year: 2022
  ident: ref_12
  article-title: Estrogen Mediates an Atherosclerotic-Protective Action via Estrogen Receptor Alpha/SREBP-1 Signaling
  publication-title: Front. Cardiovasc. Med.
  doi: 10.3389/fcvm.2022.895916
– volume: 20
  start-page: 596
  year: 2013
  ident: ref_21
  article-title: Treatment of estrogen receptor-positive breast cancer
  publication-title: Curr. Med. Chem.
  doi: 10.2174/092986713804999303
– volume: 13
  start-page: 850815
  year: 2022
  ident: ref_13
  article-title: The Effects of Menopause Hormone Therapy on Lipid Profile in Postmenopausal Women: A Systematic Review and Meta-Analysis
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2022.850815
– volume: 22
  start-page: 1395
  year: 2016
  ident: ref_40
  article-title: Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-15-1213
– volume: 68
  start-page: 394
  year: 2018
  ident: ref_1
  article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21492
– volume: 37
  start-page: 101667
  year: 2023
  ident: ref_10
  article-title: Effects of endocrine disorders on lipids and lipoproteins
  publication-title: Best Pract. Res. Clin. Endocrinol. Metab.
  doi: 10.1016/j.beem.2022.101667
– volume: 55
  start-page: 972
  year: 2006
  ident: ref_52
  article-title: Effects of raloxifene on lipid and lipoprotein levels in postmenopausal osteoporotic women with and without hypertriglyceridemia
  publication-title: Metabolism
  doi: 10.1016/j.metabol.2006.03.005
– ident: ref_27
  doi: 10.1002/9781119536604
– volume: 23
  start-page: 9
  year: 2024
  ident: ref_9
  article-title: Lipid changes during endocrine therapy in early-stage breast cancer patients: A real-world study
  publication-title: Lipids Health Dis.
  doi: 10.1186/s12944-024-02002-6
– volume: 7
  start-page: 2620
  year: 2001
  ident: ref_46
  article-title: Advances in aromatase inhibition: Clinical efficacy and tolerability in the treatment of breast cancer
  publication-title: Clin. Cancer Res.
– volume: 25
  start-page: 464
  year: 2023
  ident: ref_4
  article-title: Recent Trends in Diagnostic Biomarkers of Tumor Microenvironment
  publication-title: Mol. Imaging Biol.
  doi: 10.1007/s11307-022-01795-1
– volume: 23
  start-page: 5126
  year: 2005
  ident: ref_30
  article-title: Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2005.07.097
– volume: 14
  start-page: 4017
  year: 2023
  ident: ref_6
  article-title: Molecular profiling of aromatase inhibitor sensitive and resistant ER+ HER2-postmenopausal breast cancers
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-023-39613-z
– volume: 355
  start-page: 125
  year: 2006
  ident: ref_53
  article-title: Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa062462
– volume: 95
  start-page: 153
  year: 2006
  ident: ref_31
  article-title: Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: Effects on body composition and lipids
  publication-title: Br. J. Cancer
  doi: 10.1038/sj.bjc.6603258
– volume: 139
  start-page: 441
  year: 2013
  ident: ref_39
  article-title: A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-013-2573-3
– volume: 52
  start-page: 1852
  year: 2012
  ident: ref_38
  article-title: Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole
  publication-title: J. Clin. Pharmacol.
  doi: 10.1177/0091270011424153
– volume: 17
  start-page: 997
  year: 2010
  ident: ref_17
  article-title: Serum lipid profile changes during the menopausal transition in Chinese women: A community-based cohort study
  publication-title: Menopause
  doi: 10.1097/gme.0b013e3181dbdc30
– volume: 73
  start-page: 3168
  year: 2019
  ident: ref_45
  article-title: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
  publication-title: J. Am. Coll. Cardiol.
  doi: 10.1016/j.jacc.2018.11.002
– ident: ref_3
– volume: 11
  start-page: R35
  year: 2009
  ident: ref_34
  article-title: Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: Final results of the ATENA lipid substudy
  publication-title: Breast Cancer Res.
  doi: 10.1186/bcr2320
– volume: 1043
  start-page: 227
  year: 2017
  ident: ref_8
  article-title: Role of Estrogens in the Regulation of Liver Lipid Metabolism
  publication-title: Adv. Exp. Med. Biol.
  doi: 10.1007/978-3-319-70178-3_12
– volume: 26
  start-page: v8
  year: 2015
  ident: ref_50
  article-title: Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdv298
– volume: 14
  start-page: 478
  year: 2023
  ident: ref_56
  article-title: Precautions for patients taking tamoxifen or aromatase inhibitors
  publication-title: J. Adv. Pract. Oncol.
  doi: 10.6004/jadpro.2023.14.6.2
– volume: 8
  start-page: 1450
  year: 2009
  ident: ref_54
  article-title: Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone-receptor-positive metastatic breast cancer patients
  publication-title: Cancer Biol. Ther.
  doi: 10.4161/cbt.8.15.8959
– volume: 7
  start-page: 837
  year: 2018
  ident: ref_44
  article-title: Comparison of changes in the lipid profiles of Eastern Chinese postmenopausal women with early-stage breast cancer treated with different aromatase inhibitors: A retrospective study
  publication-title: Clin. Pharmacol. Drug Dev.
  doi: 10.1002/cpdd.420
– volume: 295
  start-page: 25
  year: 2024
  ident: ref_55
  article-title: The effect of exemestane administration on the lipid profile in women: Meta-analysis of randomised controlled trials
  publication-title: Eur. J. Obstet. Gynecol. Reprod. Biol.
  doi: 10.1016/j.ejogrb.2024.01.021
– volume: 9
  start-page: 225
  year: 2016
  ident: ref_42
  article-title: Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety
  publication-title: Cancer Prev. Res.
  doi: 10.1158/1940-6207.CAPR-15-0269
– volume: 53
  start-page: 167
  year: 2018
  ident: ref_7
  article-title: Differential Effects of Estrogen and Progestin on Apolipoprotein B100 and B48 Kinetics in Postmenopausal Women
  publication-title: Lipids
  doi: 10.1002/lipd.12011
– volume: 15
  start-page: 1159
  year: 2010
  ident: ref_36
  article-title: Effect of letrozole on plasma lipids, triglycerides, and estradiol in postmenopausal women with metastatic breast cancer
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2009-0222
– volume: 30
  start-page: 1831
  year: 2023
  ident: ref_24
  article-title: Risk of Cardiovascular Events and Lipid Profile Change in Patients with Breast Cancer Taking Aromatase Inhibitor: A Systematic Review and Meta-Analysis
  publication-title: Curr. Oncol.
  doi: 10.3390/curroncol30020142
– volume: 103
  start-page: 1299
  year: 2011
  ident: ref_22
  article-title: Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: A systematic review and meta-analysis
  publication-title: J. Natl. Cancer Inst.
  doi: 10.1093/jnci/djr242
– volume: 162
  start-page: 777
  year: 2015
  ident: ref_26
  article-title: The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations
  publication-title: Ann. Intern. Med.
  doi: 10.7326/M14-2385
– volume: 45 Pt A
  start-page: 139
  year: 2015
  ident: ref_29
  article-title: Meta-analysis in clinical trials revisited
  publication-title: Contemp. Clin. Trials.
  doi: 10.1016/j.cct.2015.09.002
– volume: 13
  start-page: R64
  year: 2011
  ident: ref_20
  article-title: Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: A retrospective cohort study
  publication-title: Breast Cancer Res.
  doi: 10.1186/bcr2901
– volume: 38
  start-page: 2283
  year: 2018
  ident: ref_11
  article-title: Estrogen Inhibits LDL (Low-Density Lipoprotein) Transcytosis by Human Coronary Artery Endothelial Cells via GPER (G-Protein-Coupled Estrogen Receptor) and SR-BI (Scavenger Receptor Class B Type 1)
  publication-title: Arterioscler. Thromb. Vasc. Biol.
  doi: 10.1161/ATVBAHA.118.310792
– volume: 14
  start-page: 445
  year: 2011
  ident: ref_49
  article-title: Impact of surgical menopause on lipid and bone metabolism
  publication-title: Climacteric
  doi: 10.3109/13697137.2011.562994
– ident: ref_2
– volume: 137
  start-page: 383
  year: 1993
  ident: ref_18
  article-title: Perimenopausal increase in serum cholesterol: A 10-year longitudinal study
  publication-title: Am. J. Epidemiol.
  doi: 10.1093/oxfordjournals.aje.a116686
– volume: 9
  start-page: 142
  year: 2017
  ident: ref_43
  article-title: Effects of tamoxifen or letrozole on lipid profile, vitamin D and estradiol serum levels in obese postmenopausal woman with breast cancer
  publication-title: Int. J. Pharm. Sci.
– volume: 159
  start-page: 111680
  year: 2022
  ident: ref_47
  article-title: The effect of tamoxifen on the lipid profile in women: A systematic review and meta-analysis of randomized controlled trials
  publication-title: Exp. Gerontol.
  doi: 10.1016/j.exger.2021.111680
– volume: 20
  start-page: 37
  year: 1960
  ident: ref_28
  article-title: A coefficient of agreement for nominal scales
  publication-title: Educ. Psychol. Meas.
  doi: 10.1177/001316446002000104
– volume: 29
  start-page: 571
  year: 2018
  ident: ref_15
  article-title: Extragonadal effects of follicle-stimulating hormone on osteoporosis and cardiovascular disease in women during menopausal transition
  publication-title: Trends. Endocrinol. Metab.
  doi: 10.1016/j.tem.2018.06.001
– volume: 169
  start-page: 1352
  year: 2009
  ident: ref_16
  article-title: Lipid changes during the menopause transition in relation to age and weight: The Study of Women’s Health Across the Nation
  publication-title: Am. J. Epidemiol.
  doi: 10.1093/aje/kwp043
– volume: 19
  start-page: 592
  year: 2008
  ident: ref_32
  article-title: The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer
  publication-title: Eur. J. Intern. Med.
  doi: 10.1016/j.ejim.2007.05.016
– volume: 19
  start-page: 168
  year: 2015
  ident: ref_19
  article-title: Association of comorbidities with breast cancer: An observational study
  publication-title: Trop. J. Med. Res.
– ident: ref_25
  doi: 10.1371/journal.pmed.1000097
– volume: 77
  start-page: 1187
  year: 2017
  ident: ref_51
  article-title: The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis
  publication-title: Drugs
  doi: 10.1007/s40265-017-0767-4
SSID ssj0000884217
Score 2.3076384
SecondaryResourceType review_article
Snippet Background: Women are typically diagnosed with estrogen receptor-positive breast cancer around the postmenopausal period when declining estrogen levels...
Women are typically diagnosed with estrogen receptor-positive breast cancer around the postmenopausal period when declining estrogen levels initiate changes in...
Background: Women are typically diagnosed with estrogen receptor-positive breast cancer around the postmenopausal period when declining estrogen levels...
SourceID pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1818
SubjectTerms Algorithms
Analysis
Blood cholesterol
Breast cancer
Cancer
Cardiac patients
Care and treatment
Cholesterol
Development and progression
Diagnosis
Drug therapy
Dyslipidemias
Estrogen
Estrogens
High density lipoprotein
Keywords
Libraries
Lipids
Medical research
Medicine, Experimental
Meta-analysis
Metabolic disorders
Postmenopausal women
Prevention
Risk factors
Science
Systematic Review
Tamoxifen
Womens health
SummonAdditionalLinks – databaseName: Health & Medical Collection (Proquest)
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEB_0BPFF_LZ6SoQDQSjXpknT-iLr4XEKK4Ie7FuZpCm34nXX3e6z_7ozbbZuRXzqQyYhdL6TyfwATsjoWWnJ-rnEYqxQ2hhRq9iVWZN7crKY8tvh-ef84lJ9WuhFOHDbhrLKvU3sDXW9cnxGfprx_RHlDjJ9t_4ZM2oU364GCI2bcCulUIWl2izMeMZCGkT0ZniWl1F2f_rdXZPRzsmtFRNH9Lc5PvBH01rJA-dzfg_uhqhRzAY234cbvn0At-fhXvwh_JptVhR6kkcSH9urpV0yho7AthZfKDq-RsEQ1bUYnhJsxbIVDNLLjcLXuNvSyj2QpeBDWfGey9Q7ccbisHkrZuLr2OxZDDcJ_cJz32G8b2nyCC7PP3w7u4gDtELslDFdnJvGF1oz1HDplJToStVkypc58UxTyKIo0_CJS5pGG7RWNlbbxhmnMqXomz2Go3bV-qcgnKutTNBmiE55b0uL1mOTYlE2dVImEbzZ_-fKhb7jDH_xo6L8g5lSHTAlgpOReD202_g32WtmWMVKSGs5DG8JaEfczqqaUWIvyTQVKoLjCSUpj5sO71leBeXdVn9ELYJX4zDP5IK01q92TEOZKaXGRkbwZJCQccNZoZWk6REUE9kZCbil93SkXV71rb25HiApC_3s__t6DnckBVdcCyfTYzjqNjv_goKjzr7sNeA3gEERqw
  priority: 102
  providerName: ProQuest
Title Aromatase Inhibitors and Plasma Lipid Changes in Postmenopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis
URI https://www.ncbi.nlm.nih.gov/pubmed/38542042
https://www.proquest.com/docview/3002910421
https://www.proquest.com/docview/3014009472
https://pubmed.ncbi.nlm.nih.gov/PMC10970985
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 2077-0383
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000884217
  issn: 2077-0383
  databaseCode: KQ8
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVEBS
  databaseName: EBSCOhost Academic Search Ultimate
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 2077-0383
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000884217
  issn: 2077-0383
  databaseCode: ABDBF
  dateStart: 20160901
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 2077-0383
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000884217
  issn: 2077-0383
  databaseCode: DIK
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2077-0383
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000884217
  issn: 2077-0383
  databaseCode: M~E
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2077-0383
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000884217
  issn: 2077-0383
  databaseCode: RPM
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 2077-0383
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000884217
  issn: 2077-0383
  databaseCode: 7X7
  dateStart: 20190101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 2077-0383
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000884217
  issn: 2077-0383
  databaseCode: BENPR
  dateStart: 20190101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 2077-0383
  dateEnd: 20250831
  omitProxy: true
  ssIdentifier: ssj0000884217
  issn: 2077-0383
  databaseCode: M48
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED_6AWMvY92ntzZoUBgMvDmyZMuDUtLS0g1SyrZA3oykSDSjdbrEge1p__ru_EVc-rQnP-gkjO90dz_rdD-AQ3R6hhv0fjYyOhSam1BrKUKbxT5xGGT1kO4Ojy-Ti4n4OpXTLWjJOJsPuHoQ2hGf1GR58_H3rz_HuOGPCHEiZP_0096iJ04wVqlt2MWQxMm8x02eX7lkpQTm3vX9vPtzehHpvl_eCEz9osmNKHT-FJ406SMb1fregy1XPINH4-aA_Dn8HS0XmINiaGJfiuu5mROZDtPFjF1hmnyrGXFVz1h9p2DF5gUjtl7qGH6n1ytcuWK0ZPR3lp1QvXrJTskulp_ZiH3vuj6z-kihWnjsSh22vU1ewOT87MfpRdhwLIRWpGkZJql3SkriHM6s4FzbTPhYuCxB5UnMXQRCDhfZyHuZamO4N9J4m1oRC4HP-CXsFIvCvQZm7czwSJtYayucM5nRxmk_1CrzsyiLAvjQfufcNg3IiQfjJkcgQkrJN5QSwGEnfFf33XhY7D0pLCf7wLWsbi4V4BtRX6t8hAifo49SIoD9niTuItsfblWet0aYx3RmiXiVDwN41w3TTKpMK9xiTTIIUREjpzyAV7WFdC8cKyk4Tg9A9WynE6De3v2RYn5d9fimwoAoU_LN_099C485ZmBUMMeH-7BTLtfuADOo0gxgO52mA9g9Obu8-jao9so_zWQiXw
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR1da9RAcKgV1Bfx22jVFSqCEJrb3WQTQeSsljvbK4It3Fu6u9nQE5s773KIT_4jf6Mz-fIi4luf8rCzy5D53p0PgF1UeoYb1H42MNqXmhtf61D6NhF55NDI6gHVDk-Oo9Gp_DgNp1vwq62FobTKVidWijqbW7oj3xP0foSxAx-8XXzzaWoUva62IzRqtjh0P75jyLZ6M36P9H3B-cGHk_2R30wV8K1UqvQjlbs4DGnKbmIl59omMhfSJRGiG6K1luhku8AGeR4qbQzPTWhyq6wUUuJX4LlX4KoUgaRe_WqqujsdlFjET9VlgEIkwd4Xe4FGIkIzGvcM39_qf8P-9XMzN4zdwS242XipbFiz1W3YcsUduDZp3uHvws_hco6uLlpANi7OZ2ZGM3uYLjL2Cb3xC81oJHbG6tKFFZsVjIYCU2PyhV6v8ORqcCajS2D2jtLiS7ZP7Ld8zYbsc9dcmtUvF9XBE1dqv22hcg9OL-Wn34ftYl64h8CszQwPtBFaW-mcSYw2TucDHSd5FiSBB6_a_5zaps85jdv4mmK8Q0RJN4jiwW4HvKjbe_wb7CURLCWhx7OsbmoXECNqn5UOFQYqqApj6cFODxKF1faXW5KnjbJYpX9Y24Pn3TLtpAS4ws3XBIORMIbiinvwoOaQDmERh5Ljdg_iHu90ANRCvL9SzM6rVuKUfxAkcfjo_3g9g-ujk8lRejQ-PnwMNzg6dpSHxwc7sF0u1-4JOmaleVpJA4Ozyxa_3z5GTpE
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR1daxNBcKgVii_it1errlARhCOX3b3snSASW0NjTSloIW_X3b09GrGXNLkgPvm__HXO3Jc5Ed_6dA87uww337vzAbCPSs9wg9rPBkb7UnPjax1K38YiGzg0srpPtcOTk8HRmfw4Dadb8KuphaG0ykYnloo6nVu6I-8Jej_C2IH3e1mdFnF6OHq3uPJpghS9tDbjNCoWOXY_vmP4tno7PkRav-R89OHLwZFfTxjwrVSq8Acqc1EY0sTd2ErOtY1lJqSLB4h6iJZbosPtAhtkWai0MTwzocmsslJIiV-B596Am0pIQelkaqra-x2UXsRVVSWBQsRB76u9RIMxQJMadYzg36ZgwxZ28zQ3DN_oDtyuPVY2rFjsLmy5_B7sTOo3-fvwc7ico9uL1pCN84uZmdH8HqbzlJ2iZ36pGY3HTllVxrBis5zRgGBqUr7Q6xWeXA7RZHQhzN5TinzBDogVl2_YkH1uG02z6hWjPHjiCu037VQewNm1_PSHsJ3Pc_cYmLWp4YE2QmsrnTOx0cbprK-jOEuDOPDgdfOfE1v3PKfRG98SjH2IKMkGUTzYb4EXVauPf4O9IoIlpADwLKvrOgbEiFppJUOFQQuqxUh6sNeBRMG13eWG5EmtOFbJHzb34EW7TDspGS538zXBYFSMYbniHjyqOKRFWESh5Ljdg6jDOy0AtRPvruSzi7KtOOUiBHEU7v4fr-ewg4KXfBqfHD-BWxx9PErJ4_092C6Wa_cUfbTCPCuFgcH5dUvfb6yqUsw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Aromatase+Inhibitors+and+Plasma+Lipid+Changes+in+Postmenopausal+Women+with+Breast+Cancer%3A+A+Systematic+Review+and+Meta-Analysis&rft.jtitle=Journal+of+clinical+medicine&rft.au=B%C3%A9rczi%2C+B%C3%A1lint&rft.au=Farkas%2C+Nelli&rft.au=Hegyi%2C+P%C3%A9ter&rft.au=T%C3%B3th%2C+Barbara&rft.date=2024-03-21&rft.pub=MDPI&rft.eissn=2077-0383&rft.volume=13&rft.issue=6&rft_id=info:doi/10.3390%2Fjcm13061818&rft.externalDocID=PMC10970985
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2077-0383&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2077-0383&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2077-0383&client=summon